STC2 and thymoma: The results showed that high expression levels of STC2 were associated with poorer OS in BLCA, COAD, ESCA, HNSC, kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), mesothelioma (MESO), sarcoma (SARC), and thymoma (THYM), but predicted better prognosis in BRCA and brain lower-grade glioma (LGG) (Figure 5A).